journal article·2016-01-02Open access

Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: Application of factorial design approach

Ganesh B. Patil, Nandkishor D. Patil, Prashant K. Deshmukh, Pravin O. Patil, Sanjay B. Bari

Abstract

Present invention relates to design of nanostructured lipid carriers (NLC) to augment oral bioavailability of Carvedilol (CAR). In this attempt, formulations of CAR-NLCs were prepared with glyceryl-monostearate (GMS) as a lipid, poloxamer 188 as a surfactant and tween 80 as a co-surfactant using high pressure homogenizer by 2(3) factorial design approach. Formed CAR-NLCs were assessed for various performance parameters. Accelerated stability studies demonstrated negligible change in particle size and entrapment efficiency, after storage at specified time up to 3 months. The promising findings in this investigation suggest the practicability of these systems for enhancement of bioavailability of drugs like CAR.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Drug Solubulity and Delivery Systems · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, H. R. Patel Institute of Pharmaceutical Education and Research, Karwand Naka, Shirpur, Maharashtra, India

References (23)

Show source-provided references
1. 10.1016/j.ejps.2010.10.00210.1016/j.ejps.2010.10.002 ↗
2. 10.1016/j.jconrel.2004.06.01510.1016/j.jconrel.2004.06.015 ↗
3. 10.1016/j.addr.2007.04.01110.1016/j.addr.2007.04.011 ↗
4. 10.1016/j.colsurfb.2010.07.02910.1016/j.colsurfb.2010.07.029 ↗
5. Jain NK · Int J Pharm Sci Rev Res · 2011 · 7 · 125
6. 10.1016/j.ijpharm.2006.11.00410.1016/j.ijpharm.2006.11.004 ↗
7. 10.1016/j.colsurfa.2007.06.00310.1016/j.colsurfa.2007.06.003 ↗
8. 10.1016/j.colsurfb.2011.02.03810.1016/j.colsurfb.2011.02.038 ↗
9. 10.1016/S0169-409X(01)00105-310.1016/S0169-409X(01)00105-3 ↗
10. 10.1016/j.jbiotec.2004.06.00710.1016/j.jbiotec.2004.06.007 ↗
11. 10.1016/S0169-409X(02)00118-710.1016/S0169-409X(02)00118-7 ↗
12. 10.1016/S0378-5173(02)00180-110.1016/S0378-5173(02)00180-1 ↗
13. Parfitt K. 1999. The Complete Drug Reference. London: Pharmaceutical Press, p. 838.
14. 10.1007/s12272-011-0106-310.1007/s12272-011-0106-3 ↗
15. 10.1080/1083745060056126510.1080/10837450600561265 ↗
16. 10.1016/j.addr.2007.04.00610.1016/j.addr.2007.04.006 ↗
17. 10.1248/cpb.58.65010.1248/cpb.58.650 ↗
18. 10.1016/j.ejpb.2004.02.01510.1016/j.ejpb.2004.02.015 ↗
19. 10.1016/j.ijpharm.2011.05.04410.1016/j.ijpharm.2011.05.044 ↗
20. 10.1007/s11051-008-9402-310.1007/s11051-008-9402-3 ↗
21. 10.1016/S0378-5173(03)00135-210.1016/S0378-5173(03)00135-2 ↗
22. 10.1016/j.colsurfb.2012.01.00110.1016/j.colsurfb.2012.01.001 ↗
23. 10.1016/j.jconrel.2004.01.00510.1016/j.jconrel.2004.01.005 ↗